{"success":true,"data":{"pressRelease":{"id":"154713","rtpr_id":"nACStlwmDa-20260929","ticker":"BBNX","exchange":"NASDAQ","all_tickers":["BBNX"],"title":"BBNX ALERT: Securities Fraud Class Action Launched Against Beta Bionics, Inc. - November 3, 2026 Deadline","author":"ACCESSWIRE","published_at":"2026-09-29T02:00:00.626Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 28, 2026 / Levi & Korsinsky, LLP announces that a securities class\naction lawsuit has been filed on behalf of investors who purchased or\notherwise acquired Beta Bionics, Inc. (NASDAQ:BBNX) securities.\n\nIf you suffered a loss on your Beta Bionics, Inc. investment and would like to\nexplore a potential recovery under the federal securities laws, Learn about\nBeta Bionics, Inc. Class Action (https://pr.report/qv2n) or contact Joseph E.\nLevi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak\nto our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Beta Bionics,\nInc. that seeks to recover losses of shareholders who were adversely affected\nby alleged securities fraud between July 30, 2025 and February 24, 2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: According to the filed complaint, defendants\nmade false and/or misleading statements and/or failed to disclose that: when\nthey portrayed the Form 483 as relating only to a difference of interpretation\nof reportable events and downplayed the seriousness of those events. Saint's\nand Feider's statements in were misleading because they touted iLet's\nperformance but omitted the thousands of safety complaints the Company had\nreceived. It was misleading for Saint to tell investors, that the Form 483\nconcerned only a minor difference in interpretation of reporting rules, and\nthat the complaints to be back-filed were only benign reports requiring no\nhospitalization, when, in fact, the Form 483 identified over 18,000 complaints\nout of less than 30,000 total iLet users, including numerous life-threatening\nhypoglycemic events that the Company had \"failed to investigate,\" or even\nreport to the FDA, with no justification. Saint and Feider further misled\ninvestors by assuring them that the Company's remediation efforts were\nadvanced and the FDA's issues were very benign,\" when they failed to\naccurately describe the scope and severity of the FDA's observations which\nmade remediation much more complex and extensive than defendants indicated to\ninvestors. Lastly, it was misleading for Saint to stress that complaint could\nbe extremely benign, and that there was no \"underlying problem in our data\nhere,\" while omitting that the Company had in fact received hundreds of\ncomplaints of life-threatening events requiring hospitalization, and that the\nFDA had raised this issue in its Form 483.\n\nWHAT'S NEXT? If you purchased Beta Bionics, Inc. stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/qv2o). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bbnx-alert-securities-fraud-class-action-launched-against-beta-b-1228326)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACStlwmDa-20260929","title":"BBNX ALERT: Securities Fraud Class Action Launched Against Beta Bionics, Inc. - November 3, 2026 Deadline","author":"ACCESSWIRE","ticker":"BBNX","created":"2026-09-29T02:00:00.626Z","tickers":["BBNX"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) /\nSeptember 28, 2026 / Levi & Korsinsky, LLP announces that a securities class\naction lawsuit has been filed on behalf of investors who purchased or\notherwise acquired Beta Bionics, Inc. (NASDAQ:BBNX) securities.\n\nIf you suffered a loss on your Beta Bionics, Inc. investment and would like to\nexplore a potential recovery under the federal securities laws, Learn about\nBeta Bionics, Inc. Class Action (https://pr.report/qv2n) or contact Joseph E.\nLevi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak\nto our team of experienced shareholder advocates.\n\nTHE LAWSUIT: A class action securities lawsuit was filed against Beta Bionics,\nInc. that seeks to recover losses of shareholders who were adversely affected\nby alleged securities fraud between July 30, 2025 and February 24, 2026.\n\nCASE DETAILS: The filed complaint alleges that defendants made false\nstatements and/or concealed that: According to the filed complaint, defendants\nmade false and/or misleading statements and/or failed to disclose that: when\nthey portrayed the Form 483 as relating only to a difference of interpretation\nof reportable events and downplayed the seriousness of those events. Saint's\nand Feider's statements in were misleading because they touted iLet's\nperformance but omitted the thousands of safety complaints the Company had\nreceived. It was misleading for Saint to tell investors, that the Form 483\nconcerned only a minor difference in interpretation of reporting rules, and\nthat the complaints to be back-filed were only benign reports requiring no\nhospitalization, when, in fact, the Form 483 identified over 18,000 complaints\nout of less than 30,000 total iLet users, including numerous life-threatening\nhypoglycemic events that the Company had \"failed to investigate,\" or even\nreport to the FDA, with no justification. Saint and Feider further misled\ninvestors by assuring them that the Company's remediation efforts were\nadvanced and the FDA's issues were very benign,\" when they failed to\naccurately describe the scope and severity of the FDA's observations which\nmade remediation much more complex and extensive than defendants indicated to\ninvestors. Lastly, it was misleading for Saint to stress that complaint could\nbe extremely benign, and that there was no \"underlying problem in our data\nhere,\" while omitting that the Company had in fact received hundreds of\ncomplaints of life-threatening events requiring hospitalization, and that the\nFDA had raised this issue in its Form 483.\n\nWHAT'S NEXT? If you purchased Beta Bionics, Inc. stock during the relevant\ntime frame - even if you still hold your shares, learn about your rights to\nseek a recovery (https://pr.report/qv2o). There is no cost or obligation to\nparticipate.\n\nWHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has\nestablished itself as a nationally-recognized securities litigation firm that\nhas secured hundreds of millions of dollars for aggrieved shareholders and\nbuilt a track record of winning high-stakes cases. The firm has extensive\nexpertise representing investors in complex securities litigation and a team\nof over 70 employees to serve our clients. For seven years in a row, Levi &\nKorsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as\none of the top securities litigation firms in the United States. Attorney\nAdvertising. Prior results do not guarantee similar outcomes.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212)363-7500\nFax: (212) 363-7171\n\nSOURCE: Levi & Korsinsky, LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bbnx-alert-securities-fraud-class-action-launched-against-beta-b-1228326)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-09-29T02:00:00.676897138Z","server_sent_at_ms":1790647200676},"received_at":"2026-09-29T02:00:00.746Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bbnx-alert-securities-fraud-class-action-launched-against-beta-b-1228326"},"analysis":{"id":"143470","press_release_id":"154713","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["underlying securities fraud allegations concern FDA Form 483 and thousands of unreported safety complaints for the iLet device","class period spans July 2025 - February 2026; potential future disclosure and settlement liability for BBNX"],"eventType":"legal_litigation","narrative":"Levi & Korsinsky announced a securities class action filed against Beta Bionics on behalf of investors who purchased BBNX securities during the July 30, 2025 to February 24, 2026 class period.\n\nThe complaint alleges executives downplayed an FDA Form 483 that identified over 18,000 complaints out of fewer than 30,000 iLet users, including allegedly life-threatening hypoglycemic events not fully investigated or reported.\n\nThis release is law-firm solicitation marketing with a November 3, 2026 lead plaintiff deadline, not an issuer disclosure; it signals ongoing litigation risk around the iLet regulatory issues rather than any new company event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm class action solicitation -- suppress, but monitor BBNX for issuer-side FDA/litigation disclosures."},"keyFigures":{"customDimensions":{"class_period":"July 30, 2025 - February 24, 2026","lead_plaintiff_deadline":"November 3, 2026","form_483_complaints_cited":"over 18,000 complaints out of less than 30,000 total iLet users"}},"quotedText":"the Form 483 identified over 18,000 complaints out of less than 30,000 total iLet users, including numerous life-threatening hypoglycemic events","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Levi & Korsinsky contact attorney"},{"name":"Ed Korsinsky, Esq.","role":"Levi & Korsinsky attorney"},{"name":"Saint","role":"alleged defendant (Beta Bionics executive per complaint)"},{"name":"Feider","role":"alleged defendant (Beta Bionics executive per complaint)"}],"products":["iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"class action target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm solicitation issued by Levi & Korsinsky on its own wire account. No certified class, no settlement, and no new issuer disclosure; boilerplate lead-plaintiff-deadline marketing."},"tickerRelevance":{"others":[],"primary":"BBNX"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRegulatoryRisk":"FDA Form 483 and safety-complaint allegations merit watching"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky announced a securities class action filed against Beta Bionics on behalf of investors who purchased BBNX securities during the July 30, 2025 to February 24, 2026 class period.\n\nThe complaint alleges executives downplayed an FDA Form 483 that identified over 18,000 complaints out of fewer than 30,000 iLet users, including allegedly life-threatening hypoglycemic events not fully investigated or reported.\n\nThis release is law-firm solicitation marketing with a November 3, 2026 lead plaintiff deadline, not an issuer disclosure; it signals ongoing litigation risk around the iLet regulatory issues rather than any new company event.","key_figures":{"customDimensions":{"class_period":"July 30, 2025 - February 24, 2026","lead_plaintiff_deadline":"November 3, 2026","form_483_complaints_cited":"over 18,000 complaints out of less than 30,000 total iLet users"}},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"Levi & Korsinsky contact attorney"},{"name":"Ed Korsinsky, Esq.","role":"Levi & Korsinsky attorney"},{"name":"Saint","role":"alleged defendant (Beta Bionics executive per complaint)"},{"name":"Feider","role":"alleged defendant (Beta Bionics executive per complaint)"}],"products":["iLet"],"companies":[{"name":"Beta Bionics, Inc.","ticker":"BBNX","relationship":"class action target"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T02:00:08.025Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false,"underlyingRegulatoryRisk":"FDA Form 483 and safety-complaint allegations merit watching"}},"durationMs":7263,"modelName":"glm-5.3-flashx"}}